Magnesium oxide and Halaven drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Magnesium oxide (magnesium) and Halaven (eribulin mesylate). Common drug interactions include interstitial lung disease among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Magnesium oxide and Halaven. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Magnesium oxide?

Magnesium oxide has active ingredients of magnesium. It is often used in migraine. eHealthMe is studying from 19,022 Magnesium oxide users. Check the latest studies of Magnesium oxide.

What is Halaven?

Halaven has active ingredients of eribulin mesylate. eHealthMe is studying from 3,881 Halaven users. Check the latest studies of Halaven.



On Jul, 29, 2026

24 people who take Magnesium oxide and Halaven together, and have interactions are studied.

Magnesium oxide and Halaven drug interactions.

What are the common drug interactions of Magnesium Oxide and Halaven, by gender? *:

female:

  1. Interstitial lung disease
  2. Pneumocystis jiroveci pneumonia (fungal infection of the lungs)
  3. Febrile neutropenia (fever with reduced white blood cells)
  4. Lymphangiosis carcinomatosa (inflammation of the lymph vessels can lead to cancer)
  5. Gait disturbance
  6. Hypoxia (low oxygen in tissues)
  7. Thrombocytopenia (decrease of platelets in blood)
  8. Thrombotic thrombocytopenic purpura (a rare blood disorder characterized by clotting in small blood vessels of the body)
  9. Nausea (feeling of having an urge to vomit)
  10. Pyrexia (fever)

male:

  1. Death
  2. Hypoxia (low oxygen in tissues)
  3. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  4. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  5. Interstitial lung disease
  6. Malignant neoplasm progression (cancer tumour came back)
  7. Muscular weakness (muscle weakness)
  8. Radiation pneumonitis (inflammation of lung due to radiation)
  9. Thrombocytopenia (decrease of platelets in blood)
  10. Thrombotic thrombocytopenic purpura (a rare blood disorder characterized by clotting in small blood vessels of the body)

What are the common drug interactions of Magnesium Oxide and Halaven, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Febrile neutropenia (fever with reduced white blood cells)

40-49:

  1. Lymphangiosis carcinomatosa (inflammation of the lymph vessels can lead to cancer)
  2. Malignant neoplasm progression (cancer tumour came back)
  3. Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
  4. Pancreatitis (inflammation of pancreas)

50-59:

  1. Gait disturbance
  2. Hypoxia (low oxygen in tissues)
  3. Interstitial lung disease
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Thrombotic thrombocytopenic purpura (a rare blood disorder characterized by clotting in small blood vessels of the body)
  6. Nausea (feeling of having an urge to vomit)
  7. Pyrexia (fever)
  8. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  9. Obstructive airways disorder (a progressive disease that makes it hard to breathe)
  10. Dysgeusia (disorder of the sense of taste)

60+:

  1. Interstitial lung disease
  2. Intestinal perforation (complete penetration of the wall of the intestine)
  3. Pleural effusion (water on the lungs)
  4. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  5. Febrile neutropenia (fever with reduced white blood cells)
  6. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  7. Neutropenia (an abnormally low number of neutrophils)
  8. Pneumonia bacterial (pneumonia associated with bacterial infection)
  9. Septic shock (shock due to blood infection)

What are the existing conditions these people have? *

  1. Breast Cancer Recurrent: 11 people, 45.83%
  2. Metastases To Liver (cancer spreads to liver): 9 people, 37.50%
  3. Metastases To Bone (cancer spreads to bone): 7 people, 29.17%
  4. Constipation: 6 people, 25.00%
  5. Cancer Pain: 6 people, 25.00%
  6. Oedema (fluid collection in tissue): 5 people, 20.83%
  7. Metastases To Lung (cancer spreads to lung): 5 people, 20.83%
  8. Breast Cancer: 5 people, 20.83%
  9. Cachexia (loss of weight): 3 people, 12.50%
  10. Breast Cancer Metastatic: 3 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Magnesium oxide and Halaven?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Magnesium oxide and Halaven:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Magnesium oxide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Halaven:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Magnesium oxide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Halaven and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on magnesium and eribulin mesylate (the active ingredients of Magnesium oxide and Halaven, respectively), and Magnesium oxide and Halaven (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: